Treatment of Midgut Neuroendocrine Tumors

In this video, Jonathan Strosberg, MD, of the Moffitt Cancer Center, discusses current options for the treatment of midgut neuroendocrine tumors; highlights results of the NETTER-1 trial, which showed improved progression-free survival with lutetium-177 (¹⁷⁷Lu)–Dotatate in this patient population; and discusses the use of radionuclide therapy in other types of neuroendocrine tumors.

Results of the phase III NETTER-1 trial were recently published in the New England Journal of Medicine, showing that treatment of well-differentiated, metastatic midgut neuroendocrine tumors with ¹⁷⁷Lu–Dotatate improved response rates (18% vs 3%) and improved the estimated rate of progression-free survival at 20 months (65.2% vs 10.8%).

Dr. Strosberg spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held last month in San Francisco.